author-photo

Chun Yew Fong

Peter MacCallum Cancer Centre

25

Papers

693

Citations

Citation Trend

Filter By

Papers (15) Sort By

Journal Conference Others

Comparison of dose modification strategies to address expected hematologic toxicities in treatment-naïve higher-risk (HR) MDS patients treated with venetoclax + azacitidine.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
MDS-158: Updated Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naïve, Higher-Risk Myelodysplastic Syndromes: Phase 1b Results

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Promising Real World Survival Data in Adult-Onset Langerhans Cell Histiocytosis: An Australasian Lymphoma Alliance 20 Year Retrospective Study

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Measurable Residual Disease (MRD) detection by Next Generation Sequencing (NGS) in Acute Lymphoblastic LEUKAEMIA (ALL)

2020 Pathology
Show All
- Source
- Cite
- Save
Citations (0)
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.

2020 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (17)
MDS-141: The Prognostic Impact of Cytogenetic Scores in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Venetoclax and Azacitidine in a Phase 1 Study

2020 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (1)
Rapid Elimination of NPM1 Mutant Measurable Residual Disease (MRD) Using Low Intensity Venetoclax-Based Combinations in Acute Myeloid Leukemia (AML)

2019 Blood
Show All
- Source
- Cite
- Save
Citations (3)
A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

2019 Blood
Show All
- Source
- Cite
- Save
Citations (8)